Who is sponsoring NCT02757521?

NCT02757521 is sponsored by Washington University School of Medicine.

What drugs are being tested in NCT02757521?

Interventions in NCT02757521: Nitrous Oxide, Placebo.

What condition does NCT02757521 study?

NCT02757521 studies Treatment- Resistant Bipolar Disorder, Bipolar Disorder, Bipolar Depressive Disorder.

Is NCT02757521 still recruiting?

NCT02757521 is currently terminated. Last updated 5 July 2019.

Are results published for NCT02757521?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-07-05 · How we verify

NCT02757521

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nitrous TRD Bipolar Depression

Terminated EARLY_PHASE1 Results posted Last updated 5 July 2019

What this trial tests

EARLY_PHASE1 trial testing Nitrous Oxide in Treatment- Resistant Bipolar Disorder in 1 participant. Terminated before completion.

Timeline

25 March 2016

Primary endpoint
6 December 2016

6 December 2016

Quick facts

Lead sponsor	Washington University School of Medicine
Phase	EARLY_PHASE1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	1
Start date	25 March 2016
Primary completion	6 December 2016
Estimated completion	6 December 2016
Sites	1 location across United States

Drugs / interventions tested

Nitrous Oxide (NITROUS OXIDE) — full drug profile →
Placebo

Conditions studied

Treatment- Resistant Bipolar Disorder — all drugs for Treatment- Resistant Bipolar Disorder →
Bipolar Disorder — all drugs for Bipolar Disorder →
Bipolar Depressive Disorder — all drugs for Bipolar Depressive Disorder →

Sponsor

Washington University School of Medicine

Who can join

Adults 18 to 75, any sex, with Treatment- Resistant Bipolar Disorder or Bipolar Disorder. Patients with the condition only — healthy volunteers not accepted.

Adverse events — posted to ClinicalTrials.gov

Time frame: 2 weeks. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Placebo

Serious: 0/1 (0%)

Deaths: 0/1

Nitrous Oxide

Serious: 0/1 (0%)

Deaths: 0

Other adverse events (3 terms — click to expand)

Reaction	System	Placebo	Nitrous Oxide
Headache	Nervous system disorders	—	—
Worsened Anxiety	Psychiatric disorders	—	—
Feeling more cold mostly in feet	General disorders	—	—

Data from ClinicalTrials.gov NCT02757521 adverse events section.

Sponsor's own description

Investigators will study approximately 64 patients with Treatment-Resistant Bipolar Depressive Disorder, defined as a failure of at least 1 antidepressants in the current depressive episode and 2 lifetime medication failures. The study will last approximately 6 to 8 weeks, involving randomization into one of two treatment groups receiving 3 one hour long inhalation treatments over a week.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
Henter ID, Park LT, Zarate CA. · · 2021 · cited 104× · PMID 33904154 · DOI 10.1007/s40263-021-00816-x
Psychopharmacology and Experimental Therapeutics for Bipolar Depression.
Jha MK, Murrough JW. · · 2019 · cited 1× · PMID 32047368 · DOI 10.1176/appi.focus.20190009

Verify or expand the search:

Other trials of Nitrous Oxide

Trials testing the same drug.

NCT07245628 — A Trial of Self-Adjusted Nitrous Versus Placebo During Office Vasectomy · EARLY_PHASE1 · recruiting
NCT05890898 — Virtual Reality vs Nitrous Oxide in Pediatric Dentistry · NA · completed
NCT04305158 — Colonoscopy Using Nitrous Oxide- A Pilot Study in the USA · EARLY_PHASE1 · completed
NCT04378426 — Nitrous Oxide for PTSD · Phase 2 · terminated
NCT04884893 — Effect of Nitrous Oxide on EEG · Phase 1 · completed

Other Washington University School of Medicine trials

Trials by the same sponsor.

NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02757521 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
Last refreshed: 5 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02757521.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing